Leqvio and Gabapentin Interaction: What Patients and Clinicians Need to Know

Does Inclisiran Interact With Gabapentin?

The direct answer is no: inclisiran and gabapentin do not share a pharmacokinetic interaction pathway. Inclisiran does not inhibit or induce CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, and it is not a substrate or inhibitor of P-glycoprotein or organic anion-transporting polypeptides [1]. Gabapentin is absorbed via the large neutral amino acid transporter in the gut and is eliminated unchanged by the kidneys. Neither drug touches the other's metabolic machinery.

Two patients co-prescribed these drugs often share a clinical profile, atherosclerotic cardiovascular disease (ASCVD) with comorbid neuropathic pain or epilepsy, and chronic kidney disease (CKD) frequently accompanies both conditions. The shared reliance on renal clearance is the thread a clinician should pull.

Why the CYP Question Does Not Apply Here

Most drug-drug interaction (DDI) concerns center on cytochrome P450 enzymes in the liver. Inclisiran is an RNA interference (RNAi) therapeutic: a small interfering RNA (siRNA) molecule conjugated to triantennary N-acetylgalactosamine (GalNAc) that targets hepatocytes directly. Once inside hepatocytes, it silences PCSK9 mRNA. The FDA label for Leqvio (NDA 214012) states explicitly that inclisiran "is not a substrate, inhibitor, or inducer of CYP enzymes or drug transporters" [1].

Gabapentin shares this CYP-free profile. It does not bind plasma proteins significantly (<3% protein-bound), undergoes no hepatic metabolism, and is excreted unchanged in urine [2]. Because neither drug uses the liver's enzymatic machinery, classical metabolic DDI screening returns a blank.

Pharmacodynamic Considerations

Inclisiran lowers LDL-cholesterol through a mechanism entirely distinct from gabapentin's CNS modulation of voltage-gated calcium channels. There is no overlapping pharmacodynamic target. Gabapentin's sedative, dizziness, and ataxia adverse effects are not amplified by inclisiran. A patient who develops somnolence on gabapentin is experiencing a gabapentin-specific effect, not a synergistic interaction with Leqvio.

Renal Clearance: The Shared Elimination Pathway

Both drugs are cleared primarily by the kidneys. This is the clinically meaningful overlap, not because they compete for the same transporter, but because a patient with impaired renal function accumulates gabapentin to a greater degree, and the same patient's inclisiran safety data in severe CKD remain limited.

Inclisiran and Renal Impairment

The ORION program included patients with mild-to-moderate renal impairment. A dedicated pharmacokinetic sub-study showed that inclisiran exposure (AUC) increased approximately 1.6-fold in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) compared to those with normal renal function [1]. The FDA label notes that no dose adjustment is required for mild or moderate CKD, but data in patients with eGFR <15 mL/min/1.73 m² or those on dialysis are limited [1].

In ORION-10 (N=1,561), which enrolled patients with ASCVD on maximally tolerated statin therapy, inclisiran 284 mg subcutaneous at 0, 3, and 6 months and then every 6 months produced a 52.3% placebo-corrected reduction in LDL-C at day 510 [3]. Injection-site reactions were the most common adverse event (2.6% vs. 0.9% placebo), and renal adverse events were not significantly elevated above placebo rates [3].

Gabapentin and Renal Impairment

Gabapentin's renal dose-adjustment table is one of the most clinically significant in outpatient prescribing. The FDA-approved prescribing information specifies dose reductions tied directly to creatinine clearance (CrCl):

• CrCl 30-59 mL/min: 200-700 mg twice daily
• CrCl 15-29 mL/min: 200-700 mg once daily
• CrCl <15 mL/min: 100-300 mg once daily
• Patients on hemodialysis: supplemental post-dialysis dosing is required [2]

Failure to adjust gabapentin dosing in CKD leads to drug accumulation, with case reports of gabapentin toxicity including encephalopathy, respiratory depression, and myoclonus in patients whose renal function declined while their gabapentin dose remained static [4].

Why This Matters for Co-Prescribed Patients

A patient receiving inclisiran for ASCVD-related hypercholesterolemia has a substantial likelihood of having CKD. The SHARP trial (N=9,270) demonstrated that dyslipidemia and CKD frequently coexist, with approximately 25% of CKD stage 3-4 patients meeting criteria for lipid-lowering therapy [5]. If that same patient has diabetic peripheral neuropathy or postherpetic neuralgia requiring gabapentin, the prescriber must track eGFR at every relevant visit and recalculate gabapentin dosing as renal function changes.

Mechanism of Inclisiran: Why It Is Uniquely Low in DDI Risk

Understanding inclisiran's mechanism clarifies why its DDI profile is so clean, and why the gabapentin question resolves quickly for most patients.

The RNAi Mechanism

Inclisiran is a double-stranded siRNA molecule. After subcutaneous injection, the GalNAc ligands bind asialoglycoprotein receptors on hepatocyte surfaces, enabling selective cellular uptake [1]. Inside the hepatocyte, inclisiran is incorporated into the RNA-induced silencing complex (RISC), which cleaves PCSK9 mRNA. With PCSK9 silenced, hepatic LDL receptors are recycled to the cell surface rather than degraded, which increases LDL-C clearance from plasma.

This intracellular, organ-specific action means inclisiran never reaches systemic concentrations high enough to interfere meaningfully with drug-metabolizing enzymes or transporters in other tissues.

Protein Binding and Distribution

Inclisiran is approximately 87% protein-bound in plasma, primarily to albumin [1]. Gabapentin's protein binding is negligible (<3%) [2]. Displacement interactions, in which a highly protein-bound drug displaces another and temporarily raises free drug concentrations, cannot occur between these two agents.

PCSK9 Inhibition Context: Who Is Taking These Two Drugs Together?

Patients co-prescribed inclisiran and gabapentin typically carry several concurrent diagnoses. Understanding that clinical portrait sharpens monitoring priorities.

The Typical Patient Profile

A 68-year-old man with type 2 diabetes, ASCVD confirmed by prior myocardial infarction, stage 3b CKD (eGFR 38 mL/min/1.73 m²), and diabetic peripheral neuropathy is a realistic co-prescription scenario. He is on atorvastatin 40 mg and ezetimibe, but his LDL-C remains 112 mg/dL, qualifying him for inclisiran under ACC/AHA guidelines. He takes gabapentin 300 mg three times daily for neuropathic pain.

His eGFR of 38 places him in moderate CKD. Gabapentin dosing at 300 mg three times daily may be at the upper edge of what his kidneys can safely clear. Adding inclisiran does not change gabapentin clearance, but the clinical encounter that initiates inclisiran is an ideal checkpoint to reassess the gabapentin dose against his current renal function.

Neuropathic Pain in ASCVD Patients

Peripheral neuropathy secondary to diabetes affects approximately 50% of patients with long-standing type 2 diabetes, according to data from the ACCORD trial cohort [6]. Gabapentin and pregabalin remain first-line agents for diabetic peripheral neuropathy per ADA Standards of Care [7]. Because diabetes is the leading modifiable risk factor for ASCVD, clinicians managing a patient's LDL-C with inclisiran will frequently encounter gabapentin already on the medication list.

Monitoring Protocol for Co-Prescribed Patients

The following monitoring framework applies to any patient receiving both inclisiran and gabapentin, stratified by renal function.

Baseline Assessment

Before initiating inclisiran in a gabapentin-treated patient, obtain:

1. Serum creatinine and calculated eGFR (CKD-EPI equation preferred)
2. Urine albumin-to-creatinine ratio to stage CKD
3. Current gabapentin total daily dose and dosing frequency
4. LDL-C, non-HDL-C, and lipoprotein(a) if not recently measured
5. A medication reconciliation scan for any drugs that might compound CNS depression with gabapentin (opioids, benzodiazepines, muscle relaxants)

Ongoing Monitoring Intervals

| eGFR Range | Inclisiran Adjustment | Gabapentin Action | Renal Monitoring | |---|---|---|---| | ≥60 mL/min/1.73 m² | Standard dosing | No adjustment needed | Every 12 months | | 30-59 mL/min/1.73 m² | Standard dosing | Reduce per CrCl table | Every 6 months | | 15-29 mL/min/1.73 m² | Use with caution; label notes limited data | Significant dose reduction | Every 3 months | | <15 mL/min/1.73 m² | Data insufficient | Specialist input required | Monthly or per nephrology |

Adverse Effect Signals to Watch

Gabapentin toxicity in a patient whose eGFR has declined often presents subtly at first. Prescribers should ask patients at every visit about new-onset dizziness, unsteady gait, or excessive daytime sedation, all of which may indicate gabapentin accumulation. These symptoms are not caused by inclisiran but can be mistaken for a new interaction if the prescriber is unaware of the renal clearance overlap.

The 2023 FDA Drug Safety Communication reinforced that gabapentinoids carry risk of serious respiratory depression, particularly when combined with CNS depressants or in patients with respiratory compromise [8]. Inclisiran does not contribute to this risk.

FDA Label Review: Inclisiran Drug Interactions Section

The Leqvio FDA prescribing information (approved December 2021, NDA 214012) addresses drug interactions in a single concise section. The label states: "No clinically significant pharmacokinetic drug interactions are predicted based on the metabolic profile of inclisiran" [1].

Formal in vitro DDI studies covered CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, P-gp, BCRP, OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3. Inclisiran showed no inhibition or induction of any of these pathways at clinically relevant concentrations [1]. Gabapentin is not a substrate of any of the transporters tested, making the double-negative confirmation straightforward.

Gabapentin Prescribing Information: Relevant Safety Data

The FDA label for gabapentin (most recently updated 2022 for the Neurontin reference listed drug) identifies renal impairment as the primary driver of dose modification [2]. It does not list inclisiran or any PCSK9 inhibitor as an interacting drug, which is expected given inclisiran's metabolic inertness.

The label's somnolence incidence data from the adjunctive epilepsy trials showed that 19.3% of gabapentin-treated adults reported somnolence versus 8.7% on placebo [2]. This effect is dose-related and worsens with renal accumulation. Inclisiran does not modify this incidence.

The American Geriatrics Society Beers Criteria (2023 update) flags gabapentinoids as potentially inappropriate in older adults due to CNS adverse effects, falls, and fractures [9]. Older patients with ASCVD receiving inclisiran fall squarely within this demographic, making renal and CNS monitoring doubly relevant.

Patient Counseling Points

Clear, actionable information reduces medication errors and adverse events in patients managing complex regimens.

What to Tell Patients Taking Both Drugs

Patients should understand that Leqvio does not change how gabapentin works in their body. The injection targets cholesterol production in the liver, and gabapentin works on nerve signaling. Neither drug speeds up or slows down the breakdown of the other.

Patients should report any new dizziness, confusion, or falls to their prescriber, not because of a drug interaction, but because these symptoms may signal that gabapentin is building up due to changes in kidney function. Annual or biannual kidney blood tests help catch this early.

Patients should also understand the Leqvio dosing schedule: one injection at the start, a second at three months, and then every six months thereafter. Missing a dose reduces the LDL-lowering benefit. In ORION-9 (N=482), patients with heterozygous familial hypercholesterolemia who completed the full dosing schedule achieved a 39.7% placebo-corrected reduction in LDL-C at day 510 [10].

Injection Site and Practical Notes

Inclisiran is administered by a healthcare professional, not self-injected at home. Patients should confirm their next injection appointment at each office visit, since the six-month interval can be easy to lose track of. Gabapentin, by contrast, is taken at home daily, and pill-count adherence is critical, especially when dose adjustments have been made for renal function.

Special Populations

Older Adults (Age &ge;65)

The ORION-10 trial enrolled patients with a mean age of 66 years, and inclisiran's efficacy and safety were consistent across age subgroups [3]. Gabapentin accumulation risk rises with age because eGFR naturally declines at approximately 1 mL/min/1.73 m² per year after age 40 [11]. An older adult whose gabapentin dose was set at age 60 may need recalculation by age 70 even without overt CKD.

Patients on Hemodialysis

Inclisiran has been studied in patients with end-stage renal disease (ESRD) on dialysis. Exposure increases, but the drug's lipid-lowering effect appears maintained. The FDA label advises caution rather than contraindication [1]. Gabapentin on hemodialysis requires supplemental dosing after each session because the drug is significantly removed by dialysis [2]. These patients need nephrology co-management of both agents.

Sex and Body Weight

Inclisiran pharmacokinetics show modest variation by body weight and sex, but these differences do not require dose adjustment [1]. Gabapentin's absorption is saturable: higher single oral doses produce disproportionately lower bioavailability because the intestinal transporter becomes saturated. This is a gabapentin-specific pharmacokinetic quirk unrelated to inclisiran co-administration.

Clinical Bottom Line

No dose adjustment of inclisiran is required when gabapentin is co-administered, and no dose adjustment of gabapentin is required specifically because of inclisiran. The prescriber's job at each visit is to reassess the patient's current eGFR and confirm that gabapentin dosing matches the renal-adjusted table in the FDA label. Patients with eGFR <60 mL/min/1.73 m² should have renal function measured at least every six months, timed conveniently to align with the inclisiran injection schedule.

In ORION-10, 52.3% LDL-C reduction was sustained at day 510 across the study population, including patients with mild-to-moderate CKD [3]. That cardiovascular benefit is not diminished by gabapentin co-prescription. The management task is straightforward: keep the kidney in view, keep the gabapentin dose renal-appropriate, and proceed with inclisiran on its standard schedule.